ARGOBIO

Argobio is a start-up studio based in Paris, France, dedicated to turning cutting-edge innovations into breakthrough biotech companies.

Argobio sources innovative early-stage projects on therapeutics from renowned European academic research institutions with a focus on rare diseases, neurological disorders, oncology and immunology. The studio selects and incubates these projects with the goal to create biotech companies and develop them up to a significant Series A financing.

Argobio provides broad expertise in the discovery and development of novel drugs with a team of highly experienced Biotech entrepreneurs. The internal team is led by Yves Ribeill, Neill Mackenzie and Rémi Soula. Thierry Laugel, Managing Partner at Kurma Partners is the President of Argobio.

Argobio was initiated by Kurma Partners, a leading Paris-based healthcare venture capital firm, and Bpifrance, the French national investment bank. Kurma and Bpifrance were joined by complementary strategic investors, Angelini Pharma, a private international pharmaceutical company, Evotec, a drug discovery alliance and development partnership company, and the Institut Pasteur, internationally renowned center for biomedical research.